Program
BHV-1300
A development code.
Its studies are mostly in Graves Disease, led by Biohaven Therapeutics.
Furthest: phase 3, since Jun 16, 20263 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biohaven Therapeutics | 33 open or running | phase 3since Jun 16, 2026 | May 12, 2025 | Sep 2027phase 1 · NCT06980649 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2025First study: phase 1 study in Graves DiseaseFirst studyNCT06980649 · 15 planned · United States, Australia
- Jun 16, 2026Phase 3 study in Graves DiseasePhase 3 reachedNCT07661056 · 300 planned · United States, Canada, Puerto Rico
- Oct 22, 2026Phase 3 study in Graves DiseaseNCT07901244 · 356 planned
Ahead
- Sep 2027Primary completion: phase 1 study in Graves DiseaseNCT06980649
- Jan 2028Primary completion: phase 3 study in Graves DiseaseNCT07661056
- Dec 2028Primary completion: phase 3 study in Graves DiseaseNCT07901244
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07901244Graves Disease | 3 | Not yet recruiting | Dec 2028 | 356 |
| NCT07661056Graves Disease · United States, Canada, Puerto Rico | 3 | Recruiting | Jan 2028 | 300 |
| NCT06980649Graves Disease · United States, Australia | 1 | Recruiting | Sep 2027 | 15 |
How it is read
Names in the registry
- “BHV-1300”, 3 entries
Codes read as this program: BHV1300.
Conditions, from the studies’ own filings
- Graves Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.